FLOATING DRUG DELIVERY SYSTEMS: AN EXTENSIVE REVIEW OF DESIGN PRINCIPLES, RECENT ADVANCEMENTS, AND CLINICAL SIGNIFICANCE

The development of Gastro-Retentive Drug Delivery Systems (GRDDS), especially Floating Drug Delivery Systems (FDDS), which extend gastric residence time and improve the bioavailability of medications with limited absorption windows, acid-soluble medications, and those requiring localized gastric action, has greatly advanced oral controlled-release drug delivery. In order to obtain dependable stomach retention, floating, swellable, expandable, mucoadhesive, and raft-forming platforms must be designed because conventional oral systems fail due to quick gastric emptying, variable motility, and partial drug release. In order to provide buoyancy and sustained release for ten to twenty-four hours, FDDS reduce dosage-form density through gas production or polymer swelling. Recent developments include super porous hydrogels that react to gastric pH and ionic conditions, nanosized citrus pectin-based in-situ rafts, and hybrid systems that combine flotation with mucoadhesion or expansion. By providing exact control over geometry, porosity, density, and multi-compartment structures, additive manufacturing (3D printing) has further revolutionized GRDDS, permitting complicated release patterns and individualized therapy. Despite their promise, GRDDS face challenges like physiological variability, inconsistent buoyancy in fasted conditions, manufacturing complexities, and regulatory requirements for proving in-vivo retention and safety. Looking ahead, there is an emphasis on multimodal systems that integrate various retention mechanisms. AI-driven formulation design can help optimize polymer behavior and buoyancy. Additionally, biomimetic devices are being developed to mimic gastric physiology.All of these developments put next-generation GRDDS in a position to be extremely flexible platforms that can support personalized medicine for a variety of gastric and upper-intestinal disorders, increase therapeutic efficacy, and decrease dosing frequency.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-10-12
DOI
https://doi.org/10.5281/zenodo.17891808
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FLOATING DRUG DELIVERY SYSTEMS: AN EXTENSIVE REVIEW OF DESIGN PRINCIPLES, RECENT ADVANCEMENTS, AND CLINICAL SIGNIFICANCE

Zenodo (CERN European Organization for Nuclear Research)
Drug Solubulity and Delivery Systems
article

FLOATING DRUG DELIVERY SYSTEMS: AN EXTENSIVE REVIEW OF DESIGN PRINCIPLES, RECENT ADVANCEMENTS, AND CLINICAL SIGNIFICANCE

article en

Abstract

The development of Gastro-Retentive Drug Delivery Systems (GRDDS), especially Floating Drug Delivery Systems (FDDS), which extend gastric residence time and improve the bioavailability of medications with limited absorption windows, acid-soluble medications, and those requiring localized gastric action, has greatly advanced oral controlled-release drug delivery. In order to obtain dependable stomach retention, floating, swellable, expandable, mucoadhesive, and raft-forming platforms must be designed because conventional oral systems fail due to quick gastric emptying, variable motility, and partial drug release. In order to provide buoyancy and sustained release for ten to twenty-four hours, FDDS reduce dosage-form density through gas production or polymer swelling. Recent developments include super porous hydrogels that react to gastric pH and ionic conditions, nanosized citrus pectin-based in-situ rafts, and hybrid systems that combine flotation with mucoadhesion or expansion. By providing exact control over geometry, porosity, density, and multi-compartment structures, additive manufacturing (3D printing) has further revolutionized GRDDS, permitting complicated release patterns and individualized therapy. Despite their promise, GRDDS face challenges like physiological variability, inconsistent buoyancy in fasted conditions, manufacturing complexities, and regulatory requirements for proving in-vivo retention and safety. Looking ahead, there is an emphasis on multimodal systems that integrate various retention mechanisms. AI-driven formulation design can help optimize polymer behavior and buoyancy. Additionally, biomimetic devices are being developed to mimic gastric physiology.All of these developments put next-generation GRDDS in a position to be extremely flexible platforms that can support personalized medicine for a variety of gastric and upper-intestinal disorders, increase therapeutic efficacy, and decrease dosing frequency.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 40%
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FLOATING DRUG DELIVERY SYSTEMS: AN EXTENSIVE REVIEW OF DESIGN PRINCIPLES, RECENT ADVANCEMENTS, AND CLINICAL SIGNIFICANCE · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS